Karyopharm files for Chapter 11 and plans a merger with Gamida Cell parent Ayrmid, backed by $55M in DIP financing; shares fall 84%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results